| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| FP.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FD.3 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FG.3 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.19 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BQ.1.1.56 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BQ.1.1.59 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| GA.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.6 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.67 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FL.2.6 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.88 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.16.20 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.34.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JD.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BQ.1.25 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.79 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| HP.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FU.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| EG.1.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.2.3.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| EY.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.35 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.18 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| EL.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BQ.1.1.44 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FU.1.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FL.4.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| EF.1.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.84 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| EU.1.1.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.97 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| CH.1.1.14 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FE.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.17 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.5.3.5 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| FL.1.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.95 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| ET.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.34 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.31 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.2.3.9 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.47 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BQ.1.1.13 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BN.1.10 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.23 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| GA.3 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XBB.1.5.58 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| GH.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |